News - Watson Pharmaceuticals, Actavis

Filter

Popular Filters

Shire prevails in US Lialda patent dispute with Watson

10-05-2013

Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

AstraZeneca in Crestor patent settlement with Actavis and EGIS Pharma

25-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a settlement agreement in its US patent…

ActavisCardio-vascularCrestorGenericsNorth AmericaPatentsPharmaceuticalrosuvastatinShionogiWatson Pharmaceuticals

Lower 4th-qtr 2012 profits at Actavis but beat expectations

19-02-2013

US generics major Actavis (NYSE: ACT, the new name for the Watson business) reported net revenue increased…

ActavisFinancialGenericsWatson Pharmaceuticals

Pfizer prevails in Rapamune patent dispute with Watson

01-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) says that the US District Court for the District of Delaware…

ActavisGenericsImmunologicalsLegalNorth AmericaPatentsPfizerPharmaceuticalRapamuneWatson Pharmaceuticals

Watson Pharma now trading as Actavis; Dr Reddy's debuts generic Clarinex Reditabs in USA

28-01-2013

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) announced last week that the company has adopted…

ActavisClarinex ReditabsDr Reddy's LaboratoriesFinancialGenericsManagementMarkets & MarketingWatson Pharmaceuticals

Watson 3rd-qtr EPS jumps 24%, as revenues rise 19%

01-11-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has reported that net income for the third quarter…

ActavisFinancialGenericsWatson Pharmaceuticals

US FTC puts divestment conditions on Watson's acquisition of Actavis

16-10-2012

The USA's Federal Trade Commission will require Watson Pharmaceuticals (NYSE: WPI) and fellow generic…

ActavisGenericsLegalMergers & AcquisitionsNorth AmericaNovartisPar PharmaceuticalsSandozWatson Pharmaceuticals

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

US FDA approves generics for Actavis and Lupin

06-07-2012

Switzerland-based generic drugmaker Actavis Group, now owned by US firm Watson Pharmaceuticals (NYSE:…

ActavisGenericsIntunivLupinLyricaNeurologicalNorth AmericaPfizerRegulationShireWatson Pharmaceuticals

FDA delays approval of QRxPharma's pain drug MoxDuo

29-06-2012

The US Food and Drug Administration has issued a Complete Response Letter (CRL) regarding the New Drug…

ActavisMoxDuoNeurologicalNorth AmericaPharmaceuticalQRxPharmaRegulationWatson Pharmaceuticals

Shire to face generic competition for Adderall XR from Actavis

25-06-2012

Shares in UK drugmaker Shire (LSE: SHP) fell around 9% to £17.82 in early trading this morning,…

ActavisAdderall XRGenericsNeurologicalNorth AmericaPharmaceuticalRegulationShireWatson Pharmaceuticals

Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip

20-05-2012

Ireland-headquartered Warner Chilcott (Nasdaq: WCRX) has filed suit against USA-based Watson Pharmaceuticals…

ActavisGenericsGlaxoSmithKlineLegalLo LoestrinMarkets & MarketingNeurologicalNorth AmericaPatentsRegulationReproductiveRequip XLWarner ChilcottWatson Pharmaceuticals

Fitch puts Watson on rating watch Negative on planned acquisition of Actavis

26-04-2012

US generics drugmaker Watson Pharmaceuticals (NYSE: WPI) has seen its rating downgraded by Fitch Ratings,…

ActavisFinancialGenericsMergers & AcquisitionsNorth AmericaWatson Pharmaceuticals

Watson Pharma confirms buy of generic group Actavis for 4.25 billion euros

26-04-2012

As has been widely rumoured over this week, Watson Pharmaceuticals (NYSE: WPI) has confirmed a definitive…

ActavisGenericsMergers & AcquisitionsWatson Pharmaceuticals

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis

29-03-2012

There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Actavis reportedly to be acquired by Watson; debuts generic Zomig

22-03-2012

Icelandic generic drugmaker Actavis is said to be in talks to be acquired by US peer Watson Pharmaceuticals…

ActavisAstraZenecaEuropeGenericsMarkets & MarketingMergers & AcquisitionsNeurologicalPatentsWatson PharmaceuticalsZolmitriptanZomig

Depomed files patent infringement suits relating to Gralise

05-03-2012

California, USA-based Depomed (Nasdaq: DEPO) yesterday filed a patent infringement law suit in the US…

ActavisDepomedGenericsGraliseIncepta PharmaceuticalsLegalNeurologicalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Watson challenges Exelon patent; wins Seasonique appeal; launches generic Kadian

13-11-2011

There was an active day for US generics drugmaker Watson Pharmaceuticals (NYSE: WPI), first, confirming…

ActavisDuramed PharmaceuticalsExelonGenericsKadianMarkets & MarketingNeurologicalNorth AmericaPatentsReproductiveSeasoniqueWatson Pharmaceuticals

Back to top